S&P 500   3,455.25 (+0.57%)
DOW   28,397.04 (+0.66%)
QQQ   284.36 (+0.06%)
AAPL   115.73 (-0.98%)
MSFT   214.94 (+0.07%)
FB   278.23 (-0.18%)
GOOGL   1,607.85 (+1.38%)
AMZN   3,172.87 (-0.38%)
TSLA   428.83 (+1.46%)
NVDA   535.45 (-1.02%)
BABA   306.43 (-0.50%)
CGC   19.99 (+2.57%)
GE   7.72 (+5.46%)
MU   54.81 (+2.81%)
AMD   79.89 (+0.87%)
T   28.27 (+5.80%)
F   8.14 (+3.69%)
ACB   4.75 (-2.06%)
GILD   60.23 (+0.03%)
NFLX   485.23 (-0.78%)
BA   169.20 (+3.26%)
NIO   27.38 (-1.72%)
DIS   127.65 (+0.81%)
S&P 500   3,455.25 (+0.57%)
DOW   28,397.04 (+0.66%)
QQQ   284.36 (+0.06%)
AAPL   115.73 (-0.98%)
MSFT   214.94 (+0.07%)
FB   278.23 (-0.18%)
GOOGL   1,607.85 (+1.38%)
AMZN   3,172.87 (-0.38%)
TSLA   428.83 (+1.46%)
NVDA   535.45 (-1.02%)
BABA   306.43 (-0.50%)
CGC   19.99 (+2.57%)
GE   7.72 (+5.46%)
MU   54.81 (+2.81%)
AMD   79.89 (+0.87%)
T   28.27 (+5.80%)
F   8.14 (+3.69%)
ACB   4.75 (-2.06%)
GILD   60.23 (+0.03%)
NFLX   485.23 (-0.78%)
BA   169.20 (+3.26%)
NIO   27.38 (-1.72%)
DIS   127.65 (+0.81%)
S&P 500   3,455.25 (+0.57%)
DOW   28,397.04 (+0.66%)
QQQ   284.36 (+0.06%)
AAPL   115.73 (-0.98%)
MSFT   214.94 (+0.07%)
FB   278.23 (-0.18%)
GOOGL   1,607.85 (+1.38%)
AMZN   3,172.87 (-0.38%)
TSLA   428.83 (+1.46%)
NVDA   535.45 (-1.02%)
BABA   306.43 (-0.50%)
CGC   19.99 (+2.57%)
GE   7.72 (+5.46%)
MU   54.81 (+2.81%)
AMD   79.89 (+0.87%)
T   28.27 (+5.80%)
F   8.14 (+3.69%)
ACB   4.75 (-2.06%)
GILD   60.23 (+0.03%)
NFLX   485.23 (-0.78%)
BA   169.20 (+3.26%)
NIO   27.38 (-1.72%)
DIS   127.65 (+0.81%)
S&P 500   3,455.25 (+0.57%)
DOW   28,397.04 (+0.66%)
QQQ   284.36 (+0.06%)
AAPL   115.73 (-0.98%)
MSFT   214.94 (+0.07%)
FB   278.23 (-0.18%)
GOOGL   1,607.85 (+1.38%)
AMZN   3,172.87 (-0.38%)
TSLA   428.83 (+1.46%)
NVDA   535.45 (-1.02%)
BABA   306.43 (-0.50%)
CGC   19.99 (+2.57%)
GE   7.72 (+5.46%)
MU   54.81 (+2.81%)
AMD   79.89 (+0.87%)
T   28.27 (+5.80%)
F   8.14 (+3.69%)
ACB   4.75 (-2.06%)
GILD   60.23 (+0.03%)
NFLX   485.23 (-0.78%)
BA   169.20 (+3.26%)
NIO   27.38 (-1.72%)
DIS   127.65 (+0.81%)
Log in
NASDAQ:VXRT

Vaxart Stock Forecast, Price & News

$5.31
+0.11 (+2.12 %)
(As of 10/22/2020 02:24 PM ET)
Add
Compare
Today's Range
$5.07
Now: $5.31▼
$5.44
50-Day Range
$4.78
MA: $6.59▼
$8.99
52-Week Range
$0.27
Now: $5.31▼
$17.49
Volume169,816 shs
Average Volume14.82 million shs
Market Capitalization$581.29 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.11
Vaxart, Inc., a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.
Read More
Vaxart logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.53 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VXRT
Previous SymbolNASDAQ:NABI
CUSIPN/A
CIK72444
Webwww.vaxart.com
Phone650-550-3500
Employees16

Debt

Debt-to-Equity RatioN/A
Current Ratio3.98
Quick Ratio3.98

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.86 million
Price / Sales58.95
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.27 per share
Price / Book19.67

Profitability

EPS (Most Recent Fiscal Year)($0.86)
Net Income$-18,650,000.00
Net Margins-281.50%
Return on Equity-84.90%
Return on Assets-44.67%

Miscellaneous

Outstanding Shares109,470,000
Market Cap$581.29 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$5.31
+0.11 (+2.12 %)
(As of 10/22/2020 02:24 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VXRT News and Ratings via Email

Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vaxart (NASDAQ:VXRT) Frequently Asked Questions

How has Vaxart's stock price been impacted by COVID-19?

Vaxart's stock was trading at $2.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VXRT stock has increased by 156.5% and is now trading at $5.31.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Vaxart?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vaxart.

When is Vaxart's next earnings date?

Vaxart is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Vaxart.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) issued its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.06. The biotechnology company had revenue of $0.52 million for the quarter, compared to the consensus estimate of $1.90 million. Vaxart had a negative net margin of 281.50% and a negative return on equity of 84.90%.
View Vaxart's earnings history.

When did Vaxart's stock split? How did Vaxart's stock split work?

Vaxart's stock reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for VXRT?

2 equities research analysts have issued twelve-month price targets for Vaxart's stock. Their forecasts range from $17.00 to $22.00. On average, they anticipate Vaxart's share price to reach $19.50 in the next year. This suggests a possible upside of 267.2% from the stock's current price.
View analysts' price targets for Vaxart.

Are investors shorting Vaxart?

Vaxart saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 17,430,000 shares, an increase of 29.8% from the August 31st total of 13,430,000 shares. Based on an average trading volume of 35,150,000 shares, the days-to-cover ratio is currently 0.5 days.
View Vaxart's Short Interest.

Who are some of Vaxart's key competitors?

Some companies that are related to Vaxart include Revolution Medicines (RVMD), SpringWorks Therapeutics (SWTX), Vaxcyte (PCVX), Sorrento Therapeutics (SRNE), Forma Therapeutics (FMTX), Editas Medicine (EDIT), Bavarian Nordic A/S (BVNRY), AlloVir (ALVR), Replimune Group (REPL), Beam Therapeutics (BEAM), Kymera Therapeutics (KYMR), Sangamo Therapeutics (SGMO), Cortexyme (CRTX), NanoString Technologies (NSTG) and Mesoblast (MESO).
View all competitors.

What other stocks do shareholders of Vaxart own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), BioNano Genomics (BNGO), ADMA Biologics (ADMA), Novavax (NVAX), OrganiGram (OGI) and Novan (NOVN).

Who are Vaxart's key executives?

Vaxart's management team includes the following people:
  • Dr. Sean N. Tucker, Founder & Chief Scientific Officer (Age 52, Pay $353.37k)
  • Ms. Margaret A. Echerd, VP, Controller & Principal Accounting Officer (Age 61, Pay $290.18k)
  • Mr. Cezar Andrei Floroiu M.B.A., CEO, Pres, Principal Financial Officer & Director (Age 47)
  • Ms. Shaily Jaini Garg, Sr. VP of Clinical Devel. & Project Management
  • Mr. Brant Biehn, Sr. VP of Commercial Operations

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Who are Vaxart's major shareholders?

Vaxart's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Strategic Wealth Management Group LLC (0.10%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Michael J Finney, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart.

Which major investors are buying Vaxart stock?

VXRT stock was bought by a variety of institutional investors in the last quarter, including Strategic Wealth Management Group LLC. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker, and Wouter Latour.
View insider buying and selling activity for Vaxart.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $5.31.

How big of a company is Vaxart?

Vaxart has a market capitalization of $581.29 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 16 workers across the globe.

What is Vaxart's official website?

The official website for Vaxart is www.vaxart.com.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.